Large-scale testing (Phase 3)Study completedNCT01866319
What this trial is testing
Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)
Who this might be right for
Melanoma
Merck Sharp & Dohme LLC 834